Healthcare Industry News: Bard
News Release - March 16, 2007
Tutogen Medical Names David C. Greenspan, Ph.D Vice President Global Research & DevelopmentALACHUA, Fla., March 16 (HSMN NewsFeed) -- Tutogen Medical, Inc., (Amex: TTG ), a leading manufacturer of sterile biological implant products made from human (allograft) and animal (xenograft) tissue, announced today that David C. Greenspan, Ph.D. has joined the Company as Vice President -- Global Research and Development.
Dr. Greenspan has more than twenty-six years of experience in the discovery, development and commercialization of innovative technologies in the fields of medical devices and high temperature ceramic coatings for severe environments. He has created intellectual property (inventor/co-inventor) in three separate technologies that have gained commercial success.
Most recently, from 2003 to the present, Dr. Greenspan has served as Vice President, Chief Technology Officer and Corporate Officer at NovaMin Technology, Inc., a development stage company in medical devices and consumer products for oral health care. He was responsible for the creation of research and development programs for the Company's oral care technology. From 1992 to 2003 Dr. Greenspan was Vice President, Chief Technology Officer and Corporate Officer at US Biomaterials Corporation, a start-up company in the field of bone regeneration products, and was responsible for creation and implementation of internal and contract research programs to commercialize medical devices based on Bioglass® technology licensed from Geltech, Inc. and the University of Florida.
Prior to that Dr. Greenspan was Vice President, Biomedical Products at Geltech, Inc., of Alachua, Fl., a start-up, advanced materials development company. He was responsible for organizing, staffing, and implementing the newly created biomedical business unit based on Bioglass® technology licensed from the University of Florida. Additional responsibilities included management of production of non-medical product line of silica based optical components.
Dr. Greenspan holds a Bachelor of Science degree in Glass Science from the New York State College of Ceramics at Alfred University and a Ph.D. in Materials Science and Engineering from the University of Florida.
Guy Mayer, president and chief executive officer of Tutogen Medical, said, "We are pleased to have a leading research and development professional the caliber of David Greenspan join our team here at Tutogen Medical. His tenured experience and his extensive knowledge in the creation and development of intellectual property will serve us well going forward."
"With more than 26 years of experience in research, development and commercialization, and 25 patents issued, Dr. Greenspan is uniquely qualified to bring together our research and development teams, enhance our new product development process, and expand our proprietary technology portfolio. We look forward to his many contributions in the years to come," Mr. Mayer concluded.
About Tutogen Medical, Inc.
Tutogen Medical, Inc. manufactures sterile biological implant products made from human (allograft) and animal (xenograft) tissue. Tutogen utilizes its Tutoplast Process® of tissue preservation and viral inactivation to manufacture and deliver sterile bio-implants used in spinal/trauma, urology, dental, ophthalmology, and general surgery procedures. The Company's Tutoplast® products are sold and distributed worldwide by Zimmer Spine and Zimmer Dental, subsidiaries of Zimmer Holdings, Inc., Davol Inc. subsidiary of C.R. Bard Inc., the Mentor Corporation (Mentor), Coloplast Corp., IOP, Inc. and through independent distributors internationally. For more information, visit the Company's Web site at http://www.tutogen.com.
Forward-Looking Statement Disclaimer: This press release contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements typically are identified by use of terms such as "may," "will," "should," "plan," "expect," "anticipate," "estimate," and similar words, although some forward-looking statements are expressed differently. These statements include, but are not limited to, statements made by the Company's Chief Executive Officer concerning the Company's recent financial performance and trends of quarterly revenue increases, progress toward profitability, the potential for growth in sales and continued market acceptance of the Company's hernia repair, breast reconstruction and new spine products, potential growth in the Company's dental and international markets, and management's excitement about the Company's future opportunities. Forward-looking statements are based on management's current expectations and are subject to certain risks and uncertainties that could cause actual results to differ materially from those set forth or implied by forward-looking statements. These and other risks are identified in the Company's filings with the Securities and Exchange Commission, including the Company's Annual Report on Form 10-K for the fiscal year ended September 30, 2006. All information in this press release is as of the date hereof, and the Company undertakes no duty to update this information unless required by law.
Source: Tutogen Medical
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.